Eli Lilly weight loss drug beats Ozempic in head-to-head study

Dow Jones

43,828.06

Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Get Started

Home
Investing
Stocks
UK
LSE
Eli Lilly And Co (0Q1G)
Eli Lilly And Co (0Q1G) News

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Eli Lilly And Co	LSE:0Q1G	London	Ordinary Share		ELI LILLY ORD SHS

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.00	0.00%	81.83						350	00:00:00

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
Pharmaceutical Preparations	34.12B	5.24B	5.5202	142.95	77.68B

Eli Lilly weight loss drug beats Ozempic in head-to-head study

Patients taking Eli Lilly & Co's new drug Mounjaro achieved significantly greater weight loss than those on Novo Nord ...

Subscribe now to see this Premium News article from

Alliance News Professional covers every UK stock in your portfolio. It goes beyond regulatory news and free web services to give your investment decisions an edge over the crowd.

Click for a FREE Trial

In The Know - Management and analyst comments that go beyond company announcements.
Flash headlines on all 2,400 London-listed companies before the news hits the open web.
Broker Ratings - The earliest tip-offs, many before the market opens.
Economic data and central bank flashes from UK, US and eurozone.
Taking AIM - Up to the minute market commentary on AIM stocks.
Over 500 news items per trading day for just £39.60 per month, and cancel at any time.

Try Alliance News FREE for 1 Month

Call us on +44 (0) 203 8794 460 to get started.